aTyr Pharma reports $68.3M cash; plans Phase 3 for efzofitimod after FDA meeting

aTYR PHARMA INC

Cash, cash equivalents, restricted cash and investments: $68.3M as of March 31, 2026.
Plans to file IND in June 2026 for a Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease; primary endpoint FVC at week 48.
Phase 3 study to enroll ~372 patients; randomized, double-blind, placebo-controlled, 54 weeks.
On track to complete enrollment in Phase 2 EFZO-CONNECT study for SSc-ILD in first half 2026.
R&D expenses $7.3M and G&A expenses $4.1M for Q1 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.